SCHEMBL521295

SCHEMBL521295

CC(O)CN1CCN(c2ccc(N)cc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
GFER P55789 2/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
DRD2 P14416 5/20 0.49
DRD3 P35462 3/20 0.49
GAA P10253 1/20 0.46
RAD52 P43351 1/20 0.46
JAK2 O60674 2/20 0.44
IGF1R P08069 1/20 0.42
HTR1A P08908 1/20 0.42
HTR7 P34969 1/20 0.42
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
TP53 P04637 1/20 0.41
DRD4 P21917 1/20 0.40
SLC6A3 Q01959 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521294 1.00 MAPT (0.54) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL1127846 0.89 MAPT (0.56) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL13419252 0.84 MAPT (0.52) MAPTALDH1A1LMNADRD2DRD3
SCHEMBL521067 0.83 DRD2 (0.48) MAPTALDH1A1DRD2DRD3JAK2
SCHEMBL521068 0.83 DRD2 (0.48) MAPTALDH1A1DRD2DRD3JAK2
SCHEMBL159281 0.81 MAPT (0.68) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL28195441 0.80 MAPT (0.56) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL17265648 0.80 ALDH1A1 (0.77) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL3027517 0.78 MAPT (0.57) MAPTGFERALDH1A1LMNAMAPK1
SCHEMBL521453 0.78 ALDH1A1 (0.59) MAPTALDH1A1LMNAMAPK1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 MAPT 3109/4885GFER 4090/4885ALDH1A1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.